Medication info
Lowbica HCT Tablet 5/40/12.5mg

Lowbica HCT Tablet 5/40/12.5mg

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Ilsung IS Co., Ltd.
Appearance
Pale yellow circular film-coated tablet
Packaging
28 tablets (14 tablets/PTP X2) / box
Approval status
Active

MFDS item code 201900767 · Approved 2019.01.31 · Insurance code 655404060

Summary

Main use
Treatment of essential hypertension not controlled with combination therapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the doses of the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy) be adjusted. However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or this medicine 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or this medicine 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or 10/40/12.5mg. ※ Refer to the following dose escalation scheme. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg □ Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). □ Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. □ Older adults (aged 65 years and over) In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults. In particular, there is very limited experience with the use of this medicine in older adults aged 75 years and over; therefore, monitor them very carefully when administering this medicine.
Child dose
Children under 18 years: The safety and efficacy have not been established; use of this medicine is not recommended.

Ingredients

Manufacturer
Ilsung IS Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with combination therapy

  • Essential hypertension
View approved original text

Combination therapy with amlodipine and olmesartan medoxomil is used in patients with essential hypertension who do not achieve adequate blood pressure control with a single drug. These drugs help lower blood pressure by dilating blood vessels and improve heart and vascular health. This treatment effectively reduces the risk of complications from hypertension and improves blood pressure control.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the doses of the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy) be adjusted. However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or this medicine 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or this medicine 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or 10/40/12.5mg. ※ Refer to the following dose escalation scheme. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg □ Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). □ Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. □ Older adults (aged 65 years and over) In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults. In particular, there is very limited experience with the use of this medicine in older adults aged 75 years and over; therefore, monitor them very carefully when administering this medicine.

Child dose

Children under 18 years: The safety and efficacy have not been established; use of this medicine is not recommended.

Precautions

This drug can cause serious harm to the fetus and newborn if taken during the second or third trimester of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. This drug is contraindicated for patients with an allergy to this drug or its components or with certain heart and kidney diseases, and for those who are pregnant or breastfeeding. It should not be used in patients with very low blood pressure, acute heart issues, or severe liver or kidney disease. Patients with reduced blood volume or impaired renal function may experience hypotension when starting this medication, so monitoring of their condition is necessary. This drug may affect kidney function, requiring regular blood tests for patients with kidney disease or those who have undergone kidney transplantation. Patients with impaired liver function or specific heart valve diseases should also use this drug with caution. The diuretic component in this medication may cause electrolyte imbalances, necessitating regular monitoring of electrolyte levels in the blood. Since blood pressure may drop too low, patients should avoid hazardous activities while taking this medication if they experience dizziness or drowsiness. This drug may interact with other medications, particularly lithium, certain pain relievers, and other antihypertensive agents, so consult a healthcare professional if taking these. The use of this drug is not recommended during breastfeeding, and if necessary, breastfeeding or the drug itself may need to be discontinued. Its safety and efficacy have not been established in pediatric patients under 18 years of age, so its use is not recommended in this population. In elderly patients, starting at a lower dose and careful monitoring is advisable, taking into account impaired kidney and liver function. In case of overdose, symptoms such as hypotension, arrhythmias, and electrolyte imbalances may occur, necessitating immediate medical attention.

Side effects

Peripheral edema, headache, dizziness, upper respiratory tract infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, loss of appetite, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, increased sensitivity, restlessness, mood changes, sleep disturbances, dizziness, orthostatic dizziness, presyncope, taste disorders, hypertonia, sensory loss, paresthesia, peripheral neuropathy, drowsiness, fainting, convulsions, loss of appetite, tremor, visual disturbances, decreased tear production, worsening of myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, change in bowel habits, bowel distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like reaction, pustular rash, exudative dermatitis, hyperhidrosis, phototoxic reaction, pruritus, purpura, Quincke's edema, rash, recurrence of lupus erythematosus, toxic skin necrosis, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, polyuria, acute renal failure, hematuria, urination disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial swelling, elevated serum creatinine, elevated blood urea, elevated serum uric acid, decreased blood potassium, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption-like intestinal disease, intestinal vascular edema, altered consciousness, drug hypersensitivity, upper abdominal pain, decreased libido, labial edema, asthenia, loss of consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flushing, nosebleeds, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This drug can deteriorate due to air or moisture, so it must be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow circular film-coated tablet

Package unit

28 tablets (14 tablets/PTP X2) / box

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.